泰立沙拉帕替尼相关指南规范与共识关键临床研究回顾课件.ppt

下载文档 降价啦

0
0
约5.18千字
约 56页
2019-09-14 发布于江苏
举报
版权申诉
保障服务

泰立沙拉帕替尼相关指南规范与共识关键临床研究回顾课件.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

Tykerb?+trastuzumab (2nd line) A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol. 2008;26(15S):A1015. Tykerb?+trastuzumab (2nd line) HR=0.77(95%CI:0.6-1.0) P=0.029 mPFS延长3.6个月 12.0 8.4 0 2 4 6 8 10 12 mPFS (weeks) Tykerb+trastuzumab Tykerb Tykerb?+trastuzumab (2nd line) A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol. 2008;26(15S):A1015. HR=2.1(95%CI:1.1-4.2) P=0.020 CBR提高1.9倍 25.2 13.2 0 5 10 15 20 25 30 CBR (%) Tykerb+trastuzumab Tykerb Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2 -positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-1130. Tykerb?+trastuzumab (2nd line) HR=0.73(95%CI:0.57-0.93) P=0.008 mPFS延长3.9个月 Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2 -positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-1130. Tykerb?+trastuzumab (2nd line) HR=0.72(95%CI:0.57-0.93) P=0.008 mPFS延长3.9个月 12.0 8.1 0 2 4 6 8 10 12 mPFS (weeks) Tykerb+trastuzumab Tykerb Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2 -positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-1130. Tykerb?+trastuzumab (2nd line) HR=2.2(95%CI:1.2-4.5) P=0.01 CBR提高1.99倍 24.7 12.4 0 5 10 15 20 25 CBR (%) Tykerb+trastuzumab Tykerb Tykerb?+trastuzumab (neoadjuvant) Tykerb?+trastuzumab (neoadjuvant) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633-640. Tykerb?+trastuzumab (neoadjuvant)